InvestSMART

BlinkLab Limited (ASX:BB1)

ALERT: Price-sensitive ASX Announcement for BB1
Current share price for BB1 : $0.670 0.08 (13.56%)+
Announcement
Release
27 Jul 2026 9:08AM
Price at Release
$0.590
Full Release
download
Summary
BlinkLab Limited has released a Quarterly Activities Report for the quarter ending 30 June 2026. The company completed a successful A$17.5 million placement to fund its FDA 510(k) autism study and other initiatives. They secured a U.S. patent for their core technology, extending to 2041, and expanded their platform into therapy evaluation through a partnership with Erasmus University Medical Center. BlinkLab also initiated a research collaboration in South America and maintained significant investor engagement globally. The financial position remains strong with approximately A$17.9 million in cash at the end of the quarter.
Key Points
  • Completed A$17.5 million placement for funding key projects
  • Secured U.S. patent for core technology up to 2041
  • Established collaboration with Erasmus University for therapy evaluation
  • Initiated research collaboration with ESPOCH in Ecuador
  • Maintained strong global investor engagement
  • Cash position at end of quarter: ~A$17.9 million
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.